Cogent Biosciences, Inc. $COGT Position Boosted by Vanguard Group Inc.

Vanguard Group Inc. lifted its holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) by 48.4% during the 4th quarter, HoldingsChannel.com reports. The firm owned 11,514,326 shares of the technology company’s stock after acquiring an additional 3,756,664 shares during the quarter. Vanguard Group Inc. owned approximately 0.08% of Cogent Biosciences worth $408,989,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in COGT. Osaic Holdings Inc. boosted its holdings in Cogent Biosciences by 41.4% during the second quarter. Osaic Holdings Inc. now owns 4,550 shares of the technology company’s stock worth $33,000 after buying an additional 1,333 shares in the last quarter. Strs Ohio bought a new stake in Cogent Biosciences during the first quarter worth approximately $36,000. GAMMA Investing LLC boosted its holdings in Cogent Biosciences by 91.7% during the fourth quarter. GAMMA Investing LLC now owns 1,369 shares of the technology company’s stock worth $49,000 after buying an additional 655 shares in the last quarter. Nisa Investment Advisors LLC boosted its holdings in Cogent Biosciences by 35.7% during the fourth quarter. Nisa Investment Advisors LLC now owns 1,855 shares of the technology company’s stock worth $66,000 after buying an additional 488 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Cogent Biosciences by 22.8% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,401 shares of the technology company’s stock worth $78,000 after buying an additional 1,003 shares in the last quarter.

Cogent Biosciences Stock Down 2.9%

COGT stock opened at $35.91 on Thursday. Cogent Biosciences, Inc. has a 12-month low of $4.55 and a 12-month high of $43.73. The company has a quick ratio of 14.23, a current ratio of 14.23 and a debt-to-equity ratio of 0.41. The company has a market cap of $6.13 billion, a price-to-earnings ratio of -16.55 and a beta of 0.37. The company has a 50 day moving average of $36.44 and a two-hundred day moving average of $34.68.

Cogent Biosciences (NASDAQ:COGT) last released its earnings results on Tuesday, May 5th. The technology company reported ($0.53) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.53). On average, equities analysts anticipate that Cogent Biosciences, Inc. will post -2.14 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Wedbush restated an “outperform” rating and set a $55.00 target price on shares of Cogent Biosciences in a report on Tuesday, March 17th. Robert W. Baird set a $35.00 price objective on shares of Cogent Biosciences in a research note on Thursday, February 19th. UBS Group raised shares of Cogent Biosciences to a “strong-buy” rating in a research note on Wednesday, January 7th. Piper Sandler raised their price objective on shares of Cogent Biosciences from $39.00 to $52.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 18th. Finally, Wall Street Zen lowered shares of Cogent Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, January 31st. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.73.

Cogent Biosciences Profile

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.